Health ❯ Healthcare

Clinical Trials

Phase 3 Trials Drug Development Drug Efficacy Patient Outcomes Phase III Trials Randomized Controlled Trials Research Studies Cancer Research Efficacy Studies Cancer Treatment

Finger-Prick Dried Blood Spot Test Shows 86% Accuracy for Alzheimer’s Biomarkers in Global Study

Researchers say the method could open remote, large-scale research access.

Novo Nordisk Launches First U.S. Weight-Loss GLP-1 Pill, Wegovy, With $149 Starter Price

Zenas' Obexelimab Meets Phase 3 Goals in IgG4-Related Disease With 56% Flare Risk Cut

FDA Approves Vanda’s Nereus, First New Motion Sickness Treatment in Over 40 Years

States Curb Medicaid Coverage as First GLP‑1 Weight‑Loss Pill Debuts and Cash Prices Fall

FDA Grants Priority Review to Axsome’s AXS-05 for Alzheimer’s Agitation, Sets April 30 PDUFA Date

FDA Issues Complete Response Letter for Corcept’s Relacorilant in Cushing’s-Related Hypertension

Samsung Plans CES Demo of 'Brain Health' Tool Targeting Early Dementia Signs

Shenzhuo Formula Improves Kidney Function Versus Irbesartan in 24-Week Diabetes Trial

FDA-Cleared Wegovy Pill Becomes First Oral GLP-1 for Weight Loss

Genmab Halts Acasunlimab to Focus on Late-Stage Cancer Portfolio

FDA Approves First Oral Weight-Loss GLP-1: Wegovy Pill to Launch in January

Edgewise Reports Favorable Interim Safety in Phase 2 HCM Trial of EDG-7500

FDA Approves First Oral GLP-1 for Obesity as Novo’s Wegovy Pill Sets January U.S. Launch

FDA Approves Aqvesme for Thalassemia Anemia, First U.S. Therapy for Both Patient Groups

AstraZeneca’s LATIFY Phase 3 Finds No Survival Benefit for Ceralasertib Plus Imfinzi in Pre-Treated NSCLC

Neurocrine’s Valbenazine Misses Phase 3 Goals in Dyskinetic Cerebral Palsy

FDA Approves Wegovy Weight-Loss Pill as First Oral GLP-1 for Obesity

FDA Grants Accelerated Approval to Subcutaneous Lunsumio for Relapsed Follicular Lymphoma

AstraZeneca Withdraws Andexxa From U.S. Market After FDA Says Risks Outweigh Benefits